Add a bookmark to get started

10 May 20214 minute read

DLA Piper represented Aphria in its US$8.2 billion business combination with Tilray

DLA Piper represented Aphria Inc. (TSX: APHA and NASDAQ: APHA) (“Aphria”)  in its recently completed reverse takeover of Tilray, Inc. (NASDAQ: TLRY) (“Tilray”). The combination of Aphria and Tilray brings together two highly complementary businesses to create the leading cannabis-focused CPG company with the largest global geographic footprint in the industry.

“We were delighted to support Aphria in this transformative transaction, which is expected to have a significant impact on the global cannabis industry,” said Christopher Giordano, the DLA Piper (US) partner who led the U.S. M&A deal team for Aphria. 

Russel Drew, the DLA Piper (Canada) partner who led the Canadian M&A deal team for Aphria, said  “The combination brings together two leading global cannabis companies. Our team was proud to assist Aphria, as lead M&A counsel, in the successful completion of this significant business combination. Our ability to provide elite global M&A assistance on significant transactions is unparalleled in the Canadian legal market.”

The DLA Piper US team was led by Christopher Giordano, and included Jon Venick, Stephen Alicanti, Rita Patel, Kira Mineroff, Sanjay Shirodkar, Carina Meleca, Mary Claire Blythe, Scott Luftig and Jennifer Cumming.

The DLA Piper Canada team was led by Russel Drew and Robert Seidel, and included Kevin Fritz, Michael Richards, Alex Roberts, Robert Fonn, Derek Bell, Sangeetha Punniyamoorthy, Christopher Pejovic, Grace Latimer and Youssef Aziz.

With more than 1,000 corporate lawyers globally, DLA Piper has a leading global M&A practice and has been the highest ranked legal advisor in the world for M&A deal volume for eleven consecutive years, according to Mergermarket's league tables.

DLA Piper’s CBD and International Cannabis practices cover the full range of corporate, intellectual ‎property, technology and R&D, employment, regulatory and litigation matters. We're advising in every ‎segment of the pharmaceutical, biopharmaceutical, wellness and medicinal sectors around the world.